[Oxidative stress in 29 HIV seropositive patients. Two-year results of a double-blind trial of diethyldithiocarbamate versus placebo].
Among 29 seropositive subjects who had participated in the HIV 87 therapeutic trial (Mérieux laboratories), the oxidative stress was evaluated at 24 months in 16 treated with diethyldithiocarbamate (dithiocarb) and in 13 who had received the placebo. No significant difference was found between these two groups, whereas the existence of an oxidative stress has been confirmed in seropositive subjects compared with controls.
Coutellier
A
A
Service de Médecine interne, Hôpital de La Salpêtrière, Paris.
Bonnefont-Rousselot
D
D
Delattre
J
J
Lopez
O
O
Jaudon
M C
MC
Herson
S
S
Emerit
J
J
D000328:Adult; D004050:Ditiocarb / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005979:Glutathione Peroxidase / Q000097:blood*; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism*; D006679:HIV Seropositivity / Q000378:metabolism*; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000097:blood*; D010919:Placebos; D012016:Reference Values; D012643:Selenium / Q000097:blood; D013482:Superoxide Dismutase / Q000097:blood; D014810:Vitamin E / Q000097:blood*
D010919:Placebos; D014810:Vitamin E; D008315:Malondialdehyde; D004050:Ditiocarb; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D012643:Selenium
Stress oxydatif chez 29 sujets séropositifs. Résultats à 2 ans d'une étude en double insu diéthyldithiocarbamate versus placebo.